Nio Y, Ohgaki K, Inamoto T, Kan N, Kodama H, Tobe T
Nihon Geka Gakkai Zasshi. 1986 Jun;87(6):680-96.
The sensitivity of cancer cells to anti-cancer agents (ACA) was assessed in 110 cases of breast cancer (87 primary cases and 23 recurrent cases). The cancer cells were cultured with ACAs: Mitomycin C (MMC), Adriamycin (ADR), 5-Fluorouracil (5-FU), Cytosine Arabinoside (Ara-C), Carboquone (CQ), Nimustine Hydrochloride (ACNU), Cis-platinum Diammine Dichloride (CPDD) or Vincristine (VCR) for 3 days and their sensitivity was estimated by the inhibition rate (I.R.) of DNA synthesis (3H-thymidine uptake) of cancer cells. The DNA synthesis was higher in recurrent cases than in primary cases. The primary cases showed high sensitivity to ADR or CQ, and the recurrent cases showed high sensitivity to ADR. Histologically, papillotubular or medullary tubular carcinoma showed high sensitivity to CQ, and scirrhous carcinoma showed high sensitivity to ADR, CQ or 5-FU. The sensitivities of medullary tubular or scirrhous carcinoma to ADR, 5-FU and CQ in patients with stage III and IV were lower than those in patients with stages I and II. No difference of ACA sensitivity was observed between estrogen receptor (+) and (-) cases. All recurrent cases were treated with 5-FU or its derivatives. The 50% survival period in the 5-FU high sensitivity (I.R. greater than 80%) group was 7.0 months and that of the low sensitivity (I.R. less than 80%) group 3.0 months, respectively.
对110例乳腺癌（87例原发性病例和23例复发性病例）评估了癌细胞对抗癌药物（ACA）的敏感性。将癌细胞与ACA一起培养：丝裂霉素C（MMC）、阿霉素（ADR）、5-氟尿嘧啶（5-FU）、阿糖胞苷（Ara-C）、卡波醌（CQ）、盐酸尼莫司汀（ACNU）、顺铂二氯二胺（CPDD）或长春新碱（VCR）3天，并通过癌细胞DNA合成（3H-胸腺嘧啶摄取）的抑制率（I.R.）来估计其敏感性。复发性病例中的DNA合成高于原发性病例。原发性病例对ADR或CQ表现出高敏感性，而复发性病例对ADR表现出高敏感性。组织学上，乳头管状或髓样管状癌对CQ表现出高敏感性，硬癌对ADR、CQ或5-FU表现出高敏感性。III期和IV期患者的髓样管状或硬癌对ADR、5-FU和CQ的敏感性低于I期和II期患者。雌激素受体（+）和（-）病例之间未观察到ACA敏感性差异。所有复发性病例均用5-FU或其衍生物治疗。5-FU高敏感性（I.R.大于80%）组的50%生存期分别为7.0个月，低敏感性（I.R.小于80%）组为3.0个月。
